1800-272-662
Shopping Cart 0
countryflagAU
Login

Sharp Therapeutics Corp.

Healthcare CA SHRX

2.25CAD
-(-%)

Last update at 2026-03-09T16:58:00Z

Day Range

2.252.25
LowHigh

52 Week Range

0.255.00
LowHigh

Fundamentals

  • Previous Close 2.25
  • Market Cap72.18M
  • Volume28841
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.93758M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown
Breakdown
Breakdown

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
SHRX
Sharp Therapeutics Corp.		 - -% 2.25 - - - 37.28
NGEN
NervGen Pharma Corp		 -0.11 1.96% 5.50 - - - 189.48 -4.5367
ARCH
Arch Biopartners Inc		 -0.01 1.30% 0.76 - - 196.47 - 53.05 -97.5918
NRX
NurExone Biologic Inc.		 -0.02 3.33% 0.58 - 6.90 - 31.03 -7.2365
MIR
MedMira Inc		 -0.01 14.29% 0.06 - - 180.71 - 236.85 -80.0318

Reports Covered

Stock Research & News

View All

Profile

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.

Sharp Therapeutics Corp.

2403 Sidney Street, Pittsburgh, PA, United States, 15203

Key Executives

Name Title Year Born
Dr. Scott F. Sneddon J.D., Ph.D. CEO, Chief Science Officer & Director 1963
Mr. Edward Jonasson CA CPA Chief Financial Officer 1969
Mr. Lorne Michael Sugarman Independent Director & Corporate Secretary 1970
Mr. Marcel P. Bruchez Ph.D. Scientific Co-Founder & CTO NA
Dr. Alan S. Waggoner Ph.D. Scientific Co-Founder and Chief Architect NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.